Follow

Submissions from 2023

Link

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)., Iain B McInnes, Akihiko Asahina, Laura C Coates, Robert Landewé, Joseph F Merola, Christopher T Ritchlin, Yoshiya Tanaka, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, and Philip Mease

Link

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)., Joseph F Merola, Robert Landewé, Iain B McInnes, Philip Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Alice B Gottlieb, Diamant Thaçi, Richard B Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, and Laura C Coates

Link

Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia., Ana Margarida Pinto, Rinie Geenen, Tor D Wager, Mark A Lumley, Winfried Häuser, Eva Kosek, Jacob N Ablin, Kirstine Amris, Jaime Branco, Dan Buskila, João Castelhano, Miguel Castelo-Branco, Leslie J Crofford, Mary-Ann Fitzcharles, Marina López-Solà, Mariana Luís, Tiago Reis Marques, Philip J Mease, Filipe Palavra, Jamie L Rhudy, Lucina Q Uddin, Paula Castilho, Johannes W G Jacobs, and José A P da Silva

Link

Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies., Emilce E Schneeberger, Gustavo Citera, Peter Nash, Josef S Smolen, Philip Mease, Enrique R Soriano, Claudia Helling, Annette E Szumski, Rajiv Mundayat, and Darío Ponce de León

Submissions from 2022

Link

Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group., Anna Antony, Richard Holland, Ashish J Mathew, Maria-Antoinetta D'Agostino, Walter P Maksymowych, Philip Mease, Niti Goel, Alexis Ogdie, Laura C Coates, Vibeke Strand, Robin Christensen, Dafna D Gladman, Ana-Maria Orbai, Ying Ying Leung, and William Tillett

Link

2021 GRAPPA Meet the Experts Session: A Summary of Presentations., April W Armstrong, Rasika M Reddy, Oliver FitzGerald, Kristina Callis Duffin, Philip S Helliwell, Philip Mease, Arthur Kavanaugh, Joseph F Merola, William Tillet, and Maarten de Wit

Link

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial., Xenofon Baraliakos, Effie Pournara, Laure Gossec, Philip J Mease, Roisin White, Eamonn O'Brien, Barbara Schulz, Helena Marzo-Ortega, and Laura C Coates

Link

Novel therapies in axial spondyloarthritis., Mohamad Bittar and Philip Mease

Link

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results., Laura C Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar

Link

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results., Laura C Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar

Link

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis., Laura C Coates, Christopher T Ritchlin, Laure Gossec, Philip S Helliwell, Proton Rahman, Alexa P Kollmeier, Xie L Xu, May Shawi, Chetan S Karyekar, Christine Contré, Wim Noël, Shihong Sheng, Yanli Wang, Stephen Xu, and Philip Mease

Link

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis., Laura C Coates, Josef S Smolen, Philip Mease, M Elaine Husni, Joseph F Merola, Eric Lespessailles, Mitsumasa Kishimoto, Lisa Macpherson, Andrew J Bradley, Rebecca Bolce, and Philip S Helliwell

Link

Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021., Laura C Coates, Enrique R Soriano, Nadia Corp, Heidi Bertheussen, Kristina Callis Duffin, Cristiano B Campanholo, Jeffrey Chau, Lihi Eder, Daniel G Fernández-Ávila, Oliver FitzGerald, Amit Garg, Dafna D Gladman, Niti Goel, Philip S Helliwell, M Elaine Husni, Deepak R Jadon, Arnon Katz, Dhruvkumar Laheru, John Latella, Ying-Ying Leung, Christine Lindsay, Ennio Lubrano, Luis Daniel Mazzuoccolo, Philip J Mease, Denis O'Sullivan, Alexis Ogdie, Wendy Olsder, Penelope Esther Palominos, Lori Schick, Ingrid Steinkoenig, Maarten de Wit, D A van der Windt, Arthur Kavanaugh, and GRAPPA Treatment Recommendations domain subcommittees

Link

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021., Laura C Coates, Enrique R Soriano, Nadia Corp, Heidi Bertheussen, Kristina Callis Duffin, Cristiano B Campanholo, Jeffrey Chau, Lihi Eder, Daniel G Fernández-Ávila, Oliver FitzGerald, Amit Garg, Dafna D Gladman, Niti Goel, Philip S Helliwell, M Elaine Husni, Deepak R Jadon, Arnon Katz, Dhruvkumar Laheru, John Latella, Ying-Ying Leung, Christine Lindsay, Ennio Lubrano, Luis Daniel Mazzuoccolo, Philip Mease, Denis O'Sullivan, Alexis Ogdie, Wendy Olsder, Penelope Esther Palominos, Lori Schick, Ingrid Steinkoenig, Maarten de Wit, D A van der Windt, and Arthur Kavanaugh

Link

The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial., Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Prasheen Agarwal, Feifei Yang, Alexa P Kollmeier, Elizabeth C Hsia, Natalie J Shiff, Bei Zhou, Chenglong Han, May Shawi, William Tillett, and Philip Mease

Link

The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial., Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Feifei Yang, Steven Peterson, Prasheen Agarwal, Alexa P Kollmeier, Elizabeth C Hsia, Chenglong Han, Natalie J Shiff, May Shawi, William Tillett, and Philip Mease

Link

Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis., Kurt de Vlam, Philip Mease, Andrew G Bushmakin, Roy Fleischmann, Alexis Ogdie, Valderilio F Azevedo, Joseph F Merola, John Woolcott, Joseph C Cappelleri, Lara Fallon, and Peter C Taylor

Link

Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations., Lihi Eder, Ashish J Mathew, Philippe Carron, Heidi Bertheussen, Juan D Cañete, May Azem, Andrea Delle Sedie, Carlo Salvarani, Roberto Ranza, Ashley Elliott, Anthony Turkiewicz, Ricardo Acayaba de Toledo, Hulya Bukulmez, Maria S Stoenoiu, Arthur M Mandelin, Michaela Koehm, Chris Lindsay, Evan Siegel, and Philip Mease

Link

Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé., Dafna D Gladman, Philip Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Frederic Lavie, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul A Deodhar, Mikkel Østergaard, and Xenofon Baraliakos

Link

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial., Dafna D Gladman, Philip Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Stephen Xu, Sean T Quinn, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul Deodhar, Mikkel Østergaard, and Xenofon Baraliakos

Link

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data., Alice B Gottlieb, Atul Deodhar, Iain B Mcinnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, Charis C Papavassilis, Piotr Jagiello, Philemon Papanastasiou, Philip Mease, and Mark Lebwohl

Link

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial., Philip S Helliwell, Philip Mease, Arthur Kavanaugh, Laura C Coates, Alexis Ogdie, Atul Deodhar, Vibeke Strand, Gregory Kricorian, Lyrica X H Liu, David Collier, and Dafna D Gladman

Link

Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study., Bruce Kirkham, Peter Nash, Delia Reina, Sandra Navarra, Erhard Quebe-Fehling, Corine Gaillez, Carlos Sastre, and Philip Mease

Link

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials., Iain B McInnes, Andrew J K Ostor, Philip Mease, William Tillett, Xenofon Baraliakos, Kurt de Vlam, Louis Bessette, Ralph Lippe, Anna Maniccia, Dai Feng, Tianming Gao, Patrick Zueger, Christopher Saffore, Koji Kato, In-Ho Song, and Atul Deodhar

Link

Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy., Philip Mease

Link

Effectiveness of 6-Month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Taylor Blachley, Blessing Dube, Robert R McLean, Nina Kim, Peter Hur, and Alexis Ogdie

Link

Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Soumya D Chakravarty, Robert R McLean, Taylor Blachley, Toana Kawashima, Iris Lin, Arthur Kavanaugh, and Alexis Ogdie

Link

Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review., Philip Mease and Atul Deodhar

Link

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis., Philip Mease, Atul A Deodhar, Désirée van der Heijde, Frank Behrens, Alan J Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, and Subhashis Banerjee

Link

Potential Impact of Sex and Body Mass Index on Response to Therapy in Psoriatic Arthritis: Post-hoc Analysis of Results From the SEAM-PsA Trial., Philip Mease, Dafna D Gladman, Joseph F Merola, Atul Deodhar, Alexis Ogdie, David H Collier, Lyrica Liu, and Arthur Kavanaugh

Link

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE., Philip J Mease, Akihiko Asahina, Dafna D Gladman, Yoshiya Tanaka, William Tillett, Barbara Ink, Deepak Assudani, Christine de la Loge, Jason Coarse, Jason Eells, and Laure Gossec

Link

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip J Mease, Alexis Ogdie, Soumya D Chakravarty, Natalie J Shiff, Iris Lin, Robert R McLean, Wendi Malley, Rebecca L Spitzer, Arthur Kavanaugh, and Joseph F Merola

Link

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials., Philip Mease, Arthur Kavanaugh, Dafna Gladman, Oliver FitzGerald, Enrique R Soriano, Peter Nash, Dai Feng, Apinya Lertratanakul, Kevin Douglas, Ralph Lippe, and Laure Gossec

Link

Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase 3 Results in DMARD-Naive Patients With Psoriatic Arthritis., Philip Mease, Arthur Kavanaugh, Alexis Ogdie, Alvin F Wells, Martin Bergman, Dafna D Gladman, Sven Richter, Lichen Teng, Shauna Jardon, and Josef S Smolen

Link

Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial., Philip Mease, Herbert Kellner, Akimichi Morita, Alan J Kivitz, Stella Aslanyan, Steven J Padula, Andrew S Topp, Ann Eldred, Frank Behrens, and Kim A Papp

Link

Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis., Philip Mease, Iain B McInnes, Lai-Shan Tam, Raji Rajalingam, Steve Peterson, Fareen Hassan, Soumya D Chakravarty, Christine Contré, Alison Armstrong, Wolf-Henning Boehncke, and Christopher Ritchlin

Link

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis., Philip Mease, Désirée van der Heijde, Bruce Kirkham, Georg Schett, Ana-Maria Orbai, Christopher Ritchlin, Joseph F Merola, Luminita Pricop, David A James, Xuan Zhu, and Gregory Ligozio

Link

COVID-19 Update for the GRAPPA 2021 Annual Meeting: Focus on COVID-19 Vaccination., Philip Mease, Kevin Winthrop, Wendy Olsder, and Jeffrey R Curtis

Link

Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database., Philip Mease, Pamela Young, David Gruben, Lara Fallon, Rebecca Germino, and Arthur Kavanaugh

Link

Instrument selection for the ASAS core outcome set for axial spondyloarthritis., Victoria Navarro-Compán, Anne Boel, Annelies Boonen, Philip Mease, Maxime Dougados, Uta Kiltz, Robert B M Landewé, Xenofon Baraliakos, Wilson Bautista-Molano, Praveena Chiowchanwisawakit, Hanne Dagfinrud, Lara Fallon, Marco Garrido-Cumbrera, Lianne Gensler, Bassel Kamal ElZorkany, Nigil Haroon, Yu Heng Kwan, Pedro M Machado, Walter Maksymowych, Anna Molto, Natasha de Peyrecave, Denis Poddubnyy, Mikhail Protopopov, Sofia Ramiro, In-Ho Song, Salima van Weely, and Désirée van der Heijde

Link

Prospective Cohort Study of Psoriatic Arthritis Risk in Patients With Psoriasis in a Real-World Psoriasis Registry., Alexis Ogdie, Ryan W Harrison, Robert R McLean, Tin-Chi Lin, Mark Lebwohl, Bruce E Strober, Joe Zhuo, Vardhaman Patel, and Philip J Mease

Link

Challenges in the Diagnosis and Assessment of Psoriatic Arthritis., Alexis Ogdie, Christine A Lindsay, Philip Mease, Kristina Callis Duffin, Cheryl F Rosen, and Stefan Siebert

Link

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies., Ana-Maria Orbai, Philip J Mease, Philip S Helliwell, Oliver FitzGerald, Dona L Fleishaker, Rajiv Mundayat, and Pamela Young

Link

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies., Christopher T Ritchlin, Philip Mease, Wolf-Henning Boehncke, John Tesser, Elena Schiopu, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, May Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F Merola, Iain B McInnes, and Atul Deodhar

Link

Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases., Stefan Schreiber, Luis Puig, João Gonçalves, Philip Mease, Remo Panaccione, and Paul Emery

Link

Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting., Carmel Stober, Iain B McInnes, Soumya Raychaudhuri, Philip Mease, Stephen R Pennington, Jose U Scher, Vinod Chandran, April W Armstrong, Maarten de Wit, Alberto Cauli, Deepak R Jadon, Thorvardur J Löve, Alexis Ogdie, Denis O'Sullivan, Leonieke J J van Mens, Christopher T Ritchlin, and Oliver FitzGerald

Link

Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis., William Tillett, Laura C Coates, Sandeep Kiri, Vanessa Taieb, Damon Willems, and Philip Mease

Link

Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects., James C Waddington, Orla Coleman, Philip Mease, Vinod Chandran, Denis O'Sullivan, Oliver FitzGerald, and Stephen R Pennington

Submissions from 2021

Link

Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative., Anna Antony, Richard Holland, Maria-Antonietta D'Agostino, Walter P Maksymowych, Heidi Bertheussen, Lori Schick, Niti Goel, Alexis Ogdie, Ana-Maria Orbai, P Højgaard, Laura C Coates, Vibeke Strand, Dafna D Gladman, Robin Christensen, Ying Ying Leung, Philip Mease, and William Tillett

Link

Domains to be considered for the core outcome set of axial spondyloarthritis: results from a 3-round Delphi survey., Anne Boel, Victoria Navarro-Compán, Annelies Boonen, Philip Mease, Uta Kiltz, Maxime Dougados, Robert Landewé, and Désirée van der Heijde

Link

Pustular Psoriasis and Associated Musculoskeletal Disorders., Kristina Callis Duffin, Hervé Bachelez, Philip J Mease, Cheryl Rosen, Amit Garg, Eric Zudak, Ori Elkayam, Joseph Merola, Jeffrey Chau, Mitsumasa Kishimoto, Victoria Furer, and Philip S Helliwell

Link

Withdrawing Ixekizumab in Patients with Psoriatic Arthritis who Achieved Minimal Disease Activity: Results from a Randomized, Double-Blind Withdrawal Study., Laura C Coates, Sreekumar G Pillai, Hasan Tahir, Ivo Valter, Vinod Chandran, Hideto Kameda, Masato Okada, Lisa Kerr, Denise Alves, So Young Park, David H Adams, Gaia Gallo, Matthew M Hufford, Maja Hojnik, Philip Mease, Arthur Kavanaugh, and SPIRIT-P3 Study Group

Link

Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results., Atul A Deodhar, Philip Mease, Proton Rahman, Victoria Navarro-Compán, Vibeke Strand, Theresa Hunter, Rebecca Bolce, Luis Leon, Steve Lauzon, and Helena Marzo-Ortega

Link

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks., Atul Deodhar, Philip Mease, Helena Marzo-Ortega, Theresa Hunter, David Sandoval, Andris Kronbergs, Steven Lauzon, Ann Leung, and Victoria Navarro-Compán

Link

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib., Kurt de Vlam, Alexis Ogdie, Andrew G Bushmakin, Joseph C Cappelleri, Roy Fleischmann, Peter C Taylor, Valderilio Azevedo, Lara Fallon, John Woolcott, and Philip J Mease

Link

Pustular Psoriasis and Associated Musculoskeletal Disorders., Kristina Callis Duffin, Hervé Bachelez, Philip J Mease, Cheryl Rosen, Amit Garg, Eric Zudak, Ori Elkayam, Joseph F Merola, Jeffrey Chau, Mitsumasa Kishimoto, Victoria Furer, and Philip S Helliwell

Link

Psoriatic arthritis., Oliver FitzGerald, Alexis Ogdie, Vinod Chandran, Laura C Coates, Arthur Kavanaugh, William Tillett, Ying Ying Leung, Maarten deWit, Jose U Scher, and Philip J Mease

Link

Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting., Dafna D Gladman, Philip S Helliwell, Denis Poddubnyy, and Philip Mease

Link

Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting., Dafna D Gladman, Philip S Helliwell, Denis Poddubnyy, and Philip J Mease

Link

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials., Alan J Kivitz, Oliver FitzGerald, Peter Nash, Shirley Pang, Valderilio F Azevedo, Cunshan Wang, and Liza Takiya

Link

Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations., Bethea A Kleykamp, Robert H Dworkin, Dennis C Turk, Zubin Bhagwagar, Penney Cowan, Christopher Eccleston, Susan S Ellenberg, Scott R Evans, John T Farrar, Roy L Freeman, Louis P Garrison, Jennifer S Gewandter, Veeraindar Goli, Smriti Iyengar, Alejandro R Jadad, Mark P Jensen, Roderick Junor, Nathaniel P Katz, J Patrick Kesslak, Ernest A Kopecky, Dmitri Lissin, John D Markman, Michael P McDermott, Philip Mease, Alec B O'Connor, Kushang V Patel, Srinivasa N Raja, Michael C Rowbotham, Cristina Sampaio, Jasvinder A Singh, Ilona Steigerwald, Vibeke Strand, Leslie A Tive, Jeffrey Tobias, Ajay D Wasan, and Hilary D Wilson

Link

The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up., M Lebwohl, A Deodhar, C E M Griffiths, M A Menter, D Poddubnyy, W Bao, V Jehl, K Marfo, P Primatesta, A Shete, V Trivedi, and P J Mease

Link

OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis: Provisional Endorsement for HAQ-DI and SF-36 PF., Ying-Ying Leung, Ana-Maria Orbai, Pil Hojgaard, Richard Holland, Ashish J Mathew, Niti Goel, Jeffrey Chau, William Tillett, Christine Lindsay, Alexis Ogdie, Laura C Coates, Dafna D Gladman, Robin Christensen, Philip Mease, and Vibeke Strand

Link

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group., Ying Ying Leung, Ana-Maria Orbai, William Tillett, Alexis Ogdie, Lihi Eder, Niti Goel, Pil Hojgaard, Richard Holland, Ashish J Mathew, Christine A Lindsay, Anna Antony, Jeffrey Chau, Robin Christensen, Laura C Coates, Philip J Mease, Vibeke Strand, Oliver FitzGerald, Maarten de Wit, Kristina Callis Duffin, and Dafna D Gladman

Link

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group., Ying Ying Leung, Ana-Maria Orbai, William Tillett, Alexis Ogdie, Lihi Eder, Niti Goel, Pil Hojgaard, Richard Holland, Ashish J Mathew, Christine A Lindsay, Anna Antony, Jeffrey Chau, Robin Christensen, Laura C Coates, Philip Mease, Vibeke Strand, Oliver FitzGerald, Maarten de Wit, Kristina Callis Duffin, and Dafna D Gladman

Link

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis., Ying Ying Leung, William Tillett, Pil Hojgaard, Ana-Maria Orbai, Richard Holland, Ashish J Mathew, Niti Goel, Jeffrey Chau, Chris Lindsay, Alexis Ogdie, Laura C Coates, Robin Christensen, Philip Mease, Vibeke Strand, and Dafna D Gladman

Link

Pain in Axial Spondyloarthritis: More to It Than Just Inflammation., Marina N Magrey and Philip J Mease

Link

Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies., Dennis McGonagle, Iain B McInnes, Atul Deodhar, Georg Schett, May Shawi, Shelly Kafka, Chetan S Karyekar, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Christopher T Ritchlin, Proton Rahman, and Philip J Mease

Link

Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis., Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Désirée van der Heijde, and Philip Mease

Link

Comparison of Clinical Manifestations in Rheumatoid Arthritis vs. Spondyloarthritis: A Systematic Literature Review., Philip Mease, Mohit Kumar Bhutani, Steven Hass, Esther Yi, Peter Hur, and Nina Kim

Link

GRAPPA 2020 Update From the Education Committee., Philip Mease, Amit Garg, Philip S Helliwell, and GRAPPA Education Committee

Link

Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials., Philip Mease, Dafna D Gladman, Arthur Kavanaugh, Dennis McGonagle, Peter Nash, Benoit Guerette, Priscila Nakasato, Michele Brunori, Lichen Teng, and Iain B McInnes

Link

Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy., Philip J Mease

Link

Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting., Philip J Mease, Leonard H Calabrese, Kristina Callis Duffin, Rebecca H Haberman, Rodrigo Firmino, Jose U Scher, Lori Schick, Kevin Winthrop, and Joseph F Merola

Link

Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting., Philip J Mease, Leonard H Calabrese, Kristina Callis Duffin, Rebecca H Haberman, Rodrigo Firmino, Jose U Scher, Lori Schick, Kevin Winthrop, and Joseph F Merola

Link

Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting., Philip J Mease, Leonard H Calabrese, Kristina Callis Duffin, Rebecca H Haberman, Rodrigo Firmino, Jose U Scher, Lori Schick, Kevin Winthrop, and Joseph F Merola

Link

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study., Philip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, Michael E Luggen, Proton Rahman, Siba P Raychaudhuri, Richard C Chou, Alan M Mendelsohn, Stephen J Rozzo, and Alice Gottlieb

Link

GRAPPA 2020 Update From the Education Committee., Philip J Mease, Amit Garg, Philip S Helliwell, and Philip S. Helliwell on behalf of the GRAPPA Education Committee

Link

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study., Philip J Mease, Robert Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Aimee Readie, Shephard Mpofu, Eumorphia Maria Delicha, Luminita Pricop, and Desirée van der Heijde

Link

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study., Philip J Mease, Apinya Lertratanakul, Kim A Papp, Filip E van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro W Keiserman, Xianwei Bu, Liang Chen, Reva M McCaskill, Patrick Zueger, Erin L McDearmon-Blondell, Aileen L Pangan, and William Tillett

Link

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis., Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair, Wolf-Henning Boehncke, and Christopher Ritchlin

Link

Comparison of Men and Women With Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip J Mease, Robert R McLean, Blessing Dube, Mei Liu, Sabrina Rebello, Meghan Glynn, Esther Yi, Yujin Park, and Alexis Ogdie

Link

Dr. Mease et al reply., Philip Mease, Robert R McLean, Blessing Dube, Mei Liu, Sabrina Rebello, Meghan Glynn, Esther Yi, Yujin Park, and Alexis Ogdie

Link

Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry., Philip Mease, Scott Stryker, Mei Liu, Bob Salim, Sabrina Rebello, Mahdi Gharaibeh, and David H Collier

Link

IL-23 and axial disease: do they come together?, Philip Mease and Filip van den Bosch

Link

Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study., Peter Nash, Philip Mease, Bruce Kirkham, Atul Singhal, Erhard Quebe-Fehling, Luminita Pricop, and Corine Gaillez

Link

The ASAS-OMERACT core domain set for axial spondyloarthritis., V Navarro-Compán, A Boel, A Boonen, Philip Mease, R Landewé, U Kiltz, M Dougados, X Baraliakos, W Bautista-Molano, H Carlier, P Chiowchanwisawakit, H Dagfinrud, N de Peyrecave, B El-Zorkany, L Fallon, K Gaffney, M Garrido-Cumbrera, L S Gensler, N Haroon, Y H Kwan, P M Machado, W P Maksymowych, D Poddubnyy, M Protopopov, S Ramiro, B Shea, I H Song, S van Weely, and D van der Heijde

Link

Evaluation of Clinical Diagnosis of Axial Psoriatic Arthritis (PsA) or Elevated Patient-reported Spine Pain in CorEvitas' PsA/Spondyloarthritis Registry., Alexis Ogdie, Taylor Blachley, Paul R Lakin, Blessing Dube, Robert R McLean, Peter Hur, and Philip Mease

Link

Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group., Melissa Oliver, Aruni Jayatilleke, Eveline Wu, Farzana Nuruzzaman, Cassyanne Aguiar, Aleksander Lenert, Micol Romano, Gabriele Simonini, Samir Shah, Matthew Hollander, Alhanouf Alsaleem, Emily Fox, Alexander Theos, Athimalaipet V Ramanan, Anja Schnabel, Sivia Lapidus, Lori Tucker, Karen Onel, Seza Ozen, Fatma Dedeoglu, Polly J Ferguson, Beverley Shea, Jonathan Akikusa, Christian Hedrich, Philip Mease, and Yongdong Zhao

Link

Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies., Ana-Maria Orbai, M Elaine Husni, Dafna D Gladman, Ying Ying Leung, Stefan Siebert, William Tillett, Marijn Vis, Olivier Chambenoit, Xiangyi Meng, and Philip J Mease

Link

Biopsychosocial rehabilitation for inflammatory arthritis and osteoarthritis: A systematic review and meta-analysis of randomized trials., Morten B Pedersen, Peter Thinggaard, Rinie Geenen, Marianne U Rasmussen, Maarten De Wit, Lyn March, Philip Mease, Ernest Choy, Philip G Conaghan, Lee Simon, Anne Faber Hansen, Simon Tarp, Berit Schiøttz-Christensen, Carsten B Juhl, Sabrina M Nielsen, Kirstine Amris, and Robin Christensen

Link

Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study., Lourdes M Perez-Chada, Rebecca H Haberman, Vinod Chandran, Cheryl F Rosen, Christopher Ritchlin, Lihi Eder, Philip Mease, Soumya Reddy, Alexis Ogdie, Joseph F Merola, and Jose U Scher

Link

Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting., Lourdes M Perez-Chada, Alison Kohn, Alice B Gottlieb, April W Armstrong, Lihi Eder, Philip J Mease, Alexis Ogdie, Vibeke Strand, and Joseph F Merola

Link

Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting., Lourdes M Perez-Chada, Alison Kohn, Alice B Gottlieb, April W Armstrong, Lihi Eder, Philip J Mease, Alexis Ogdie, Vibeke Strand, and Joseph F Merola

Link

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)., Denis Poddubnyy, Xenofon Baraliakos, Filip Van den Bosch, Jürgen Braun, Laura C Coates, Vinod Chandran, Torsten Diekhoff, Floris A van Gaalen, Lianne S Gensler, Niti Goel, Alice B Gottlieb, Désirée van der Heijde, Philip S Helliwell, Kay Geert A Hermann, Deepak Jadon, Robert G Lambert, Walter P Maksymowych, Philip Mease, Peter Nash, Fabian Proft, Mikhail Protopopov, Joachim Sieper, Murat Torgutalp, and Dafna D Gladman

Link

Axial involvement in psoriatic arthritis: An update for rheumatologists., Denis Poddubnyy, Deepak R Jadon, Filip Van den Bosch, Philip J Mease, and Dafna D Gladman

Link

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis., Proton Rahman, Philip J Mease, Philip S Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P Kollmeier, Elizabeth C Hsia, Bei Zhou, Xiwu Lin, May Shawi, Chetan S Karyekar, and Chenglong Han

Link

Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis., Proton Rahman, Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, Philip J Mease, Alice B Gottlieb, Shelly Kafka, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, May Shawi, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Paraneedharan Ramachandran, Yanli Zhuang, and Iain B McInnes

Link

Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study., Marie Skougaard, Tanja S Jørgensen, Mia J Jensen, Christine Ballegaard, Jørgen Guldberg-Møller, Alexander Egeberg, Robin Christensen, Peter Benzin, Zara R Stisen, Joseph F Merola, Laura C Coates, Vibeke Strand, Philip Mease, and Lars Erik Kristensen

Link

Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting., Carmel Stober, Deepak R Jadon, April W Armstrong, Vinod Chandran, Maarten de Wit, Philip S Helliwell, Philip J Mease, Alexis Ogdie, Denis O'Sullivan, Stephen R Pennington, Thorvardur Löve, Alberto Cauli, Leonieke van Mens, Robin Waxman, Jose U Scher, Anne Barton, Christopher T Ritchlin, and Oliver FitzGerald